What are the common testosterone doses used in hormone replacement therapy for postmenopausal women?

Common Testosterone Doses in HRT for Postmenopausal Women

For postmenopausal women with hypoactive sexual desire disorder (HSDD), testosterone therapy should be administered in doses that approximate physiological testosterone concentrations for premenopausal women, typically 300 mcg/day via transdermal patch or 4.4-8.8 mg/day via transdermal gel. 1

Guideline-Recommended Dosing Framework

The 2019 Global Consensus Position Statement provides the most authoritative guidance on testosterone dosing for women 1. The key principle is that doses must approximate physiological premenopausal testosterone concentrations - this is critical because:

• Higher doses (supraphysiological levels) from injectables, pellets, or compounded preparations are explicitly not recommended 1
• The evidence base supporting efficacy and safety applies only to physiological dosing 1

Specific Dose Ranges by Formulation

Transdermal Patch (Most Studied)

• Standard dose: 300 mcg/day 2
• This was the most extensively studied formulation in randomized controlled trials
• Achieved testosterone levels in the high-normal premenopausal range when used with transdermal estrogen 2
• Lower doses (150 mcg/day) showed no benefit; higher doses (450 mcg/day) produced supraphysiological levels 2

Transdermal Gel

• 4.4 mg/day: Raises testosterone to mid-to-high normal range 3
• 8.8-13.2 mg/day: Produces supraphysiological levels (not recommended) 3
• The 4.4 mg dose is the appropriate physiological replacement dose for women 3

Transdermal Cream

• 5 mg/day: Restores testosterone to premenopausal reference range 4
• 10 mg/day showed only 30% increase over 5 mg dose, suggesting diminishing returns 4

Critical Dosing Considerations

Avoid these formulations entirely:

• Subcutaneous testosterone implants produce unphysiological levels for 1-2 months post-insertion 5
• Oral testosterone undecanoate shows unpredictable absorption with inappropriate peak levels 5
• Injectable testosterone preparations (not studied adequately in women)
• Compounded preparations (variable quality, no standardization) 1

Monitoring requirements:

• No specific testosterone cutoff level differentiates women with versus without sexual dysfunction 1
• Treatment decisions should be symptom-based, not solely laboratory-driven 1
• When monitoring is performed, target testosterone levels in the premenopausal physiological range

Clinical Context and Pitfalls

The evidence supporting testosterone therapy in postmenopausal women is specific to HSDD - it cannot be generalized to other conditions 1. The typical clinical response is modest but meaningful: approximately one additional satisfying sexual event per month compared to placebo 1, 2.

Common pitfall: Using male testosterone formulations or doses. The FDA-approved testosterone gels for men 6 deliver 20.25-81 mg daily - these doses are 10-20 times higher than appropriate female dosing and will cause virilization.

Safety profile at physiological doses:

• Mild increases in acne and facial hair are common but manageable 1
• No increased risk of serious adverse events at physiological doses 1
• Oral testosterone adversely affects lipid profiles and is not recommended 1
• Safety data beyond 24 months are limited 1

The regulatory gap in the United States (no FDA-approved testosterone formulation for women) has led to widespread use of compounded preparations with variable quality 7. When prescribing, prioritize standardized pharmaceutical-grade transdermal formulations at the doses outlined above, even if off-label use is required.